Vyvanse is a brand name of lisdexamfetamine, approved by the FDA in the following formulation(s):
VYVANSE (lisdexamfetamine dimesylate - capsule; oral)
Manufacturer: SHIRE DEVELOPMENT
Approval date: February 23, 2007
Strength(s): 30MG, 50MG, 70MG [RLD]
Manufacturer: SHIRE DEVELOPMENT
Approval date: December 10, 2007
Strength(s): 20MG, 40MG, 60MG
Has a generic version of Vyvanse been approved?
No. There is currently no therapeutically equivalent version of Vyvanse available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vyvanse. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Abuse-resistant amphetamine compounds
Patent 7,105,486
Issued: September 12, 2006
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Rob & Piccariello; Thomas
Assignee(s): New River Pharmaceuticals Inc.
The invention describes compounds, compositions and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- June 29, 2023✓
- June 29, 2023✓
- June 29, 2023
Abuse resistant lysine amphetamine compounds
Patent 7,223,735
Issued: May 29, 2007
Inventor(s): Mickle; Travis & Krishnan; Suma & Moncrief; James Scott & Lauderback; Christopher & Bishop; Barney & Oberlender; Rob & Piccariello; Thomas
Assignee(s): New River Pharmaceuticals Inc.
The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- June 29, 2023✓
- June 29, 2023
Abuse-resistant amphetamine prodrugs
Patent 7,655,630
Issued: February 2, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLC
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- February 24, 2023✓
- February 24, 2023
Abuse-resistant amphetamine prodrugs
Patent 7,659,253
Issued: February 9, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLC
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- February 24, 2023✓✓✓
- February 24, 2023
Abuse-resistant amphetamine prodrugs
Patent 7,659,254
Issued: February 9, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLC
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- February 24, 2023✓
- February 24, 2023
Abuse resistant lysine amphetamine compounds
Patent 7,662,787
Issued: February 16, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Rob & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLC
The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- February 24, 2023✓
- February 24, 2023
Abuse-resistant amphetamine prodrugs
Patent 7,662,788
Issued: February 16, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLC
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- February 24, 2023✓
- February 24, 2023
Abuse-resistant amphetamine prodrugs
Patent 7,671,030
Issued: March 2, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLC
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- February 24, 2023✓✓
- February 24, 2023
Abuse-resistant amphetamine prodrugs
Patent 7,671,031
Issued: March 2, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLC
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- February 28, 2023✓
- February 28, 2023
Abuse-resistant amphetamine prodrugs
Patent 7,674,774
Issued: March 9, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLC
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- March 18, 2023✓✓
- March 18, 2023
Abuse-resistant amphetamine prodrugs
Patent 7,678,770
Issued: March 16, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLC
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- March 25, 2023✓
- March 25, 2023
Abuse-resistant amphetamine prodrugs
Patent 7,678,771
Issued: March 16, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLC
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- March 25, 2023✓✓
- March 25, 2023
Abuse-resistant amphetamine prodrugs
Patent 7,687,466
Issued: March 30, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLC
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- February 24, 2023✓
- February 24, 2023
Abuse-resistant amphetamine prodrugs
Patent 7,687,467
Issued: March 30, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLC
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- April 8, 2023✓✓
- April 8, 2023
Abuse-resistant amphetamine prodrugs
Patent 7,700,561
Issued: April 20, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLC
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- June 29, 2023✓
- June 29, 2023
Abuse-resistant amphetamine prodrugs
Patent 7,713,936
Issued: May 11, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLC
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- February 24, 2023✓
- February 24, 2023
Abuse-resistant amphetamine prodrugs
Patent 7,718,619
Issued: May 18, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLC
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- February 24, 2023✓✓
- February 24, 2023
Abuse-resistant amphetamine prodrugs
Patent 7,723,305
Issued: May 25, 2010
Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
Assignee(s): Shire LLC
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Patent expiration dates:
- February 24, 2023✓✓
- February 24, 2023
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- April 23, 2011 - NEW PATIENT POPULATION
- February 23, 2012 - NEW CHEMICAL ENTITY
- April 5, 2013 - LABELING REVISIONS RELATED TO CLINICAL STUDIES
- November 10, 2013 - NEW PATIENT POPULATION
- January 31, 2015 - MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
See also...
- Vyvanse Consumer Information (Drugs.com)
- Vyvanse Consumer Information (Wolters Kluwer)
- Vyvanse Consumer Information (Cerner Multum)
- Vyvanse Advanced Consumer Information (Micromedex)
- Vyvanse AHFS DI Monographs (ASHP)
- Lisdexamfetamine Consumer Information (Wolters Kluwer)
- Lisdexamfetamine Consumer Information (Cerner Multum)
- Lisdexamfetamine dimesylate Advanced Consumer Information (Micromedex)
- Lisdexamfetamine Dimesylate AHFS DI Monographs (ASHP)
No comments:
Post a Comment